Leaders at the Bell with John McCamant, Medical Tech StockLeter, March 24, 2026

John McCamant, editor of Medical Technology Stock Letter and a biotechnology expert with over 35 years of experience, discusses the sector's outlook and emerging opportunities at the NYSE. McCamant expresses cautious optimism about biotech's macro environment, noting that recent interest rate movements and potential stabilization of geopolitical tensions—particularly regarding Iran—could create favorable conditions for the sector. He emphasizes the classic investment principle of buying during market uncertainty, referencing the strong stock movements observed on March 23, 2026, following signals of diplomatic progress. McCamant frames pullbacks as healthy opportunities for entry, especially given the sector's strong fundamentals.

The conversation focuses extensively on the GLP-1 obesity and diabetes drug market, which McCamant describes as potentially the largest pharmaceutical category in history, projected to reach $100-150 billion. He analyzes the competitive dynamics between Novo Nordisk and Eli Lilly, noting Lily's recent advances with their first oral GLP-1 formulation and direct-to-consumer distribution strategy. McCamant highlights the multifaceted health benefits of these metabolic drugs beyond weight loss, including applications for type 2 diabetes, hypertension, and sleep apnea. He identifies merger and acquisition opportunities in the space, specifically mentioning CellDex as a potential target due to its wholly owned assets, phase two clinical data demonstrating proof of concept, and pipeline candidates addressing multiple autoimmune and inflammatory conditions.